Your browser doesn't support javascript.
loading
Respiratory Syncytial Virus-Related Complications and Healthcare Costs Among a Medicare-Insured Population in the United States.
DeMartino, Jessica K; Lafeuille, Marie-Hélène; Emond, Bruno; Rossi, Carmine; Wang, Jingru; Liu, Stephanie; Lefebvre, Patrick; Krishnarajah, Girishanthy.
Afiliação
  • DeMartino JK; Real World Value & Evidence, Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
  • Lafeuille MH; Analysis Group, Inc, Montreal, Quebec, Canada.
  • Emond B; Analysis Group, Inc, Montreal, Quebec, Canada.
  • Rossi C; Analysis Group, Inc, Montreal, Quebec, Canada.
  • Wang J; Analysis Group, Inc, Menlo Park, California, USA.
  • Liu S; Analysis Group, Inc, Menlo Park, California, USA.
  • Lefebvre P; Analysis Group, Inc, Montreal, Quebec, Canada.
  • Krishnarajah G; Real World Value & Evidence, Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
Open Forum Infect Dis ; 10(5): ofad203, 2023 May.
Article em En | MEDLINE | ID: mdl-37213421
ABSTRACT

Background:

Literature describing respiratory syncytial virus (RSV)-related complications in older adults in the United States is scarce. This study described risk factors of RSV-related complications and healthcare costs of Medicare-insured patients aged ≥60 years with medically attended RSV.

Methods:

100% Medicare Research Identifiable Files (1 January 2007-31 December 2019) were used to identify adults aged ≥60 years with RSV (index first diagnosis date). Predictors of ≥1 RSV-related complication (ie, pneumonia, acute respiratory failure, congestive heart failure, hypoxia/dyspnea, non-RSV lower/upper respiratory tract infections, or chronic respiratory disease) during the up to 6-month post-RSV diagnosis period were identified. Patients with all aforementioned diagnoses during the 6 months pre-index could not be evaluated for a complication and were therefore ineligible for analyses. Differences between 6-month pre- and post-index total all-cause and respiratory/infection-related healthcare costs were assessed.

Results:

Overall, 175 392 patients with RSV were identified. Post-RSV diagnosis, 47.9% had ≥1 RSV-related complication, with mean time-to-event of 1.0 month. The most common complications were pneumonia (24.0%), chronic respiratory disease (23.6%), and hypoxia or dyspnea (22.0%). Baseline predictors of ≥1 RSV-related complication included having previous diagnoses for complication/comorbidity listed in the Methods, hypoxemia, chemotherapy, chest radiograph, stem cell transplant, and anti-asthmatic and bronchodilator use. Total all-cause and respiratory/infection-related healthcare costs were $7797 and $8863 higher, respectively, post-index versus pre-index (both P < .001).

Conclusions:

In this real-world study, almost half of patients with medically attended RSV experienced an RSV-related complication within 1 month post-RSV diagnosis, and costs significantly increased post-diagnosis. Having a complication/comorbidity pre-RSV predicted a higher risk of developing a different complication post-RSV infection.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article